FY2017 EPS Estimates for Cerecor Inc. Raised by Analyst (CERC)
Cerecor Inc. (NASDAQ:CERC) – Research analysts at Zacks Investment Research increased their FY2017 earnings per share estimates for shares of Cerecor in a research report issued on Thursday. Zacks Investment Research analyst D. Bautz now anticipates that the company will post earnings per share of $0.83 for the year, up from their prior estimate of ($0.80). Zacks Investment Research also issued estimates for Cerecor’s Q4 2017 earnings at ($0.13) EPS, FY2018 earnings at ($0.59) EPS and FY2019 earnings at ($0.61) EPS.
Cerecor (NASDAQ:CERC) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.15. Cerecor had a return on equity of 212.90% and a net margin of 51.71%. The company had revenue of $0.16 million during the quarter. WARNING: “FY2017 EPS Estimates for Cerecor Inc. Raised by Analyst (CERC)” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.dailypolitical.com/2017/11/15/fy2017-eps-estimates-for-cerecor-inc-raised-by-analyst-cerc.html.
Other research analysts have also issued research reports about the company. TheStreet raised Cerecor from an “e+” rating to a “c-” rating in a report on Wednesday, November 8th. ValuEngine raised Cerecor from a “strong sell” rating to a “sell” rating in a report on Tuesday, November 7th.
Shares of Cerecor (NASDAQ:CERC) opened at $1.05 on Monday. Cerecor has a 52 week low of $0.34 and a 52 week high of $5.60. The firm has a market capitalization of $26.32, a P/E ratio of 101.00 and a beta of 2.13.
In related news, major shareholder Armistice Capital Master Fund bought 39,479 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were acquired at an average price of $0.76 per share, with a total value of $30,004.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders bought 684,465 shares of company stock worth $471,395. Corporate insiders own 10.70% of the company’s stock.
Cerecor Company Profile
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.